James K. Mccloskey MD

Dr. McCloskey, interim chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, considers whether most hematologists and oncologists are aware that molecular tests are appropriate for newly diagnosed acute myelogenous leukemia (AML) patients. (Additional OBR interviews with Dr. McCloskey include: Molecular testing in acute myelogenous leukemia, James McCloskey, M.D, considers the application of the FLT3 test in newly diagnosed AML patients, FLT3 mutation influences treatment decisions in AML, and The reliability of the companion diagnostic test for FLT3.